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 B lymphocytes undergo two successive and 
regulated genomic modifi cations to generate the 
repertoire of specifi cities that allows them to 
cope with an almost infi nite number of anti-
gens (for review see [ 1, 2 ]). Early in develop-
ment, the B cell receptor is assembled by V(D)J 
recombination, a site-specifi c recombination 
initiated by the lymphocyte-specifi c proteins 
RAG1 and RAG2, thus allowing the forma-
tion of the primary B cell repertoire. B cells re-
shape this repertoire in response to antigenic 
stimulation through two processes, class switch 
recombination (CSR) and somatic hypermuta-
tion (SHM), to generate secreted antibodies and 
memory B cells with improved antigen-bind-
ing capacities. SHM allows the introduction of 
point mutations, mainly in DNA encoding the 
V (variable) region of both rearranged heavy 
and light chain Ig genes, whereas CSR replaces 
the  μ heavy chain constant (C) region by down-
stream C sequences (  ,   , or   ), for the ex-
pression of IgG, IgE, or IgA, respectively. Both 
processes, SHM and CSR, are initiated by a B 
cell – specifi c enzyme, activation-induced cyti-
dine deaminase (AID). AID was fi rst discovered 
and identifi ed by Muramatsu et al. as a gene dif-
ferentially expressed in cells induced to undergo 
isotype switching, and in centroblasts of mouse 
germinal centers ( 3 ). Its inactivation in mice 
abolishes both SHM and CSR in activated B 
cells ( 4 ), and a similar phenotype is observed 
in humans, the type 2 hyper-IgM syndrome 
(HIGM2) corresponding to the clinical mani-
festation of the inactivation of AID ( 5 ). 
 AID is closely related to APOBEC-1, which 
is an RNA-editing deaminase that targets the 
apolipoprotein B transcript and induces the 
formation of a shorter polypeptide by generat-
ing a premature stop codon ( 6 ). Genetic and bio-
chemical analyses have, however, provided many 
lines of evidence that AID directly modifi es 
DNA at the Ig locus by carrying out deamina-
tion of cytidine into uracil in exposed regions 
of single-stranded DNA (for review see [ 7 ]). 
CORRESPONDENCE  
 Claude-Agn è s Reynaud: 
 reynaud@necker.fr 
 OR 
 Jean-Claude Weill: 
 weill@necker.fr
 Abbreviations used: AID, acti-
vation-induced cytidine deami-
nase; CSR, class switch 
recombination; HA, hemagglu-
tinin; KI, knock-in; LMB, lep-
tomycin B; MFI, mean 
fl uorescence intensity; MW, 
molecular weight; NES, nuclear 
export signal; NLS, nuclear 
localization signal; SHM, so-
matic hypermutation. 
 The online version of this article contains supplemental material. 
 Proteasomal degradation restricts the nuclear 
lifespan of AID 
 Said  Aoufouchi , 1  Ahmad  Faili , 1  Carole  Zober , 1  Orietta  D ’ Orlando , 2 
 Sandra  Weller , 1  Jean-Claude  Weill , 1 and  Claude-Agn è s  Reynaud 1 
 1 Institut National de la Sant é et de la Recherche M é dicale U783, D é veloppement du Syst è me Immunitaire, and Universit é Paris 
Descartes, Facult é de M é decine, Site Necker-Enfants Malades, 75730 Paris Cedex 15, France 
 2 Dipartimento di Scienze e Tecnologie Biomediche, M.A.T.I. Center of Excellence, Universita degli Studi di Udine, 
33100 Udine, Italy 
 Activation-induced cytidine deaminase (AID) initiates all postrearrangement processes that 
diversify the immunoglobulin repertoire by specifi c deamination of cytidines at the immu-
noglobulin (Ig) locus. As uncontrolled expression of AID is potentially mutagenic, different 
types of regulation, particularly nucleocytoplasmic shuttling, restrict the likelihood of AID –
 deoxyribonucleic acid encounters. We studied additional mechanisms of regulation affect-
ing the stability of the AID protein. No modulation of protein accumulation according to 
the cell cycle was observed in a Burkitt ’ s lymphoma cell line. In contrast, the half-life of 
AID was markedly reduced in the nucleus, and this destabilization was accompanied by a 
polyubiquitination that was revealed in the presence of proteasome inhibitors. The same 
compartment-specifi c degradation was observed in activated mouse B cells, and also in a 
non – B cell line. No specifi c lysine residues could be linked to this degradation, so it remains 
unclear whether polyubiquitination proceeds through several alternatives sites or through 
the protein N terminus. The nuclear-restricted form of AID displayed enhanced mutagenic-
ity at both Ig and non-Ig loci, most notably at  TP53 , suggesting that modulation of nuclear 
AID content through proteasomal degradation may represent another level of control of 
AID activity. 
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of the proteins, whether they were linked to EGFP or not, 
had a comparable half-life (Fig. S1 B). IL-4 was added to the 
culture medium in this experiment to facilitate analysis, as it 
induced a two- to threefold increase in protein expression, an 
increase that was shown by Western blot analysis to aff ect both 
alleles comparably (unpublished data). In the presence of lep-
tomycin B (LMB), which is an inhibitor of CRM1-mediated 
nuclear export, accumulation of AID-EGFP in the nucleus 
took place in a similar manner to the WT protein, suggesting 
that the shuttling of AID-EGFP between the nucleus and 
cytoplasm is not altered either (Fig. S1 C). Collectively, these 
data validate the use of the AID-EGFP knocked-in protein to 
investigate the regulation of the endogenous AID, and indi-
cate that fusion with EGFP does not aff ect the stability or the 
traffi  cking of AID within the cell. 
 We therefore used this KI clone to ask whether the AID 
protein is expressed in a specifi c phase of the cell cycle. A 
BL2 clone with one knock-out and one KI allele was selected 
because it displayed a brighter EGFP fl uorescence, which 
facilitates such a study. Exponentially growing cells in the 
presence of IL-4 were submitted to elutriation, a selection pro-
cedure based on the size and density of the cell, which allows 
The induced lesion triggers an error-prone repair cascade 
leading to the introduction of mutations in the Ig variable re-
gion or to double-strand breaks in switch regions allowing 
the rejoining of distantly located sequences. To modify bases 
on DNA, AID must be localized in the nucleus; however, 
data from several studies using either cell fractionation, mi-
croscopic examination of cells expressing AID fused to EGFP 
or immunohistological staining of lymphoid tissues, showed 
that AID localizes predominantly in the cytoplasm ( 8 – 12 ). 
This localization was shown to result, as for APOBEC1, from 
a constant nucleocytoplasmic shuttling mediated by the CRM1 
pathway, in which nuclear export dominates ( 9 – 11 ). Active 
export has been clearly assigned to a nuclear export signal 
(NES) located in the C-terminal part of AID. The role of an 
N-terminal bipartite nuclear localization signal (NLS) remains 
in debate, but whether directly or indirectly, point mutations 
in this domain can clearly abolish the nuclear translocation of 
AID ( 13 ). 
 In a transgenic mouse model, constitutive expression of 
AID has been associated with the onset of tumors, particu-
larly tumors of thymic origin ( 14 ). More recent data have 
clearly demonstrated the implication of AID in the induction 
of translocations between the c-myc and the heavy chain lo-
cus, similar to those observed in Burkitt ’ s lymphoma ( 15 – 17 ). 
Therefore, the identifi cation of AID as a potential tumor in-
ducer has brought to light the importance of its regulation 
during the germinal center reaction. In this study, we report 
that the stability of AID is related to its subcellular localiza-
tion, with the AID protein being destabilized in the nucleus 
through proteasomal-mediated degradation. Nuclear poly-
ubiquitination of AID thus appears as another level of regula-
tion that participates in controlling the access of this enzyme 
to its DNA target. The possibility that polyubiquitination may 
compete or interact with other posttranslational modifi cations 
modulating AID function is further discussed. 
 RESULTS 
 No cell-cycle regulation of AID expression at either 
the transcriptional or the posttranscriptional level 
 To facilitate the analysis of regulatory signals aff ecting the ex-
pression level of the AID protein, knock-in (KI) of the EGFP 
coding sequence at the  AICDA locus was performed by 
homologous recombination in the BL2 cell line. EGFP was 
fused in frame with exon 5 at the 3  end of the AID coding 
sequence, with the only other modifi cation being the inser-
tion of a loxP site in the intronic sequence between exons 2 
and 3 ( Fig. 1 A ) after Cre-mediated excision of the hygro-
mycin resistance marker. The expression of the AID protein 
from both KI and WT alleles was then compared and ap-
peared to be similar. Their respective half-lives were as-
sessed by [ 35 S]methionine/cysteine pulse-chase labeling and 
immuno precipitation with anti-AID monoclonal antibodies 
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20070950/DC1; see the characterization of the anti-
AID monoclonal antibodies used in this study in Fig. S2). 
Quantifi cation of radiolabeled AID indicated that both forms 
 Figure 1.  Variation of AID expression during the cell cycle. 
(A) EGFP KI at the  AICDA locus in BL2 cells. The AID – EGFP KI construct 
includes the EGFP sequence inserted in-frame in exon 5 at the 3  end of 
the AID coding region and a hygromycin resistance (hygro R ) gene fl anked 
by loxP sites. Confi guration of the targeted  AICDA locus is depicted after 
Cre-mediated excision of the hygro R gene. (B) Expression of AID-EGFP 
throughout the cell cycle. 48 h after IL-4 addition (10 ng/ml), AID-EGFP KI 
BL2 cells were fractionated according to their cell cycle status using 
counterfl ow elutriation. Collected fractions were stained with propidium 
iodide and analyzed for both DNA content and AID-EGFP MFI. Data for 
fractions 12, 30, and 39 are shown in C. (C) Cell cycle analysis and AID-
EGFP expression level of the BL2 KI cell line with and without IL-4, and of 
representative elutriated fractions, corresponding to the different phases 
of cell cycle: G1 (fr.12), S (fr. 30), and G2/M (fr. 39). 
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protein localization was confi rmed by fl uorescence micros-
copy, in the presence or absence of LMB ( Fig. 2 C ). Muta-
tions of three hydrophobic residues within the NES blocked 
the exit of the fusion protein from the nucleus, which is in 
agreement with previous studies ( 9 ). Mutations in the NLS, 
performed as described by Shinkura et al. ( 13 ), completely 
prevented its entry into the nucleus as evidenced upon LMB 
treatment ( Fig. 2 C ), thus confi rming the requirement for 
precise residues within the putative NLS to drive AID either 
directly or indirectly into the nucleus. The fl uorescence in-
tensity of the expressed AID-EGFP protein was monitored 
by analyzing three diff erent clones for each mutant or WT 
construct, a representative example being shown in  Fig. 2 B 
for each of them. We noticed that expression levels varied 
considerably according to the subcellular localization of the 
AID-EGFP protein, while being similar between diff erent 
clones harboring the same construct.  Fig. 2 B shows that, 
compared with WT-AID (mean fl uorescence intensity [MFI] = 
350), the cytoplasmic AID (Mut-NLS) exhibits a stronger 
expression (MFI = 1,340), whereas expression of the nuclear 
AID (Mut-NES) was by far the lowest (MFI = 60). Because 
all proteins have been expressed using the same expression 
vector driven by the same promoter, the level of expression 
of the fusion protein is likely to refl ect its accumulation, and 
consequently its stability, within the cell. Our data therefore 
suggest that AID displays a diff erent stability depending on 
the specifi c cell compartment in which it is located. The per-
centage of induced cells varied between the constructs as 
well, always being lower for mutNES-AID clones, a coun-
terselection probably related to the higher mutagenicity of 
nuclear AID (see section The NES-AID-GFP protein is mu-
tagenic in the BL2 cell line). 
 To investigate further the relationship between the cellular 
localization of the AID protein and its stability, we performed 
[ 35 S]methionine/cysteine pulse-chase labeling of BL2 cells 
expressing either WT, nuclear, or cytoplasmic AID-EGFP. 
Protein levels were quantifi ed, after immunoprecipitation 
with anti-EGFP antibodies, by autoradiography of PAGE-
fractionated immunoprecipitated products ( Fig. 3, A – C ). 
The half-life of the nuclear AID-EGFP protein was estimated 
as   2.5 h, compared with   8 h for the WT and 18 – 20 h for 
the cytoplasmic protein ( Fig. 3 D ). To confi rm this observa-
tion, the diff erent BL2 subclones were incubated with cyclo-
heximide to block protein synthesis, and the decay of the 
protein was followed by the decrease of its fl uorescence in-
tensity. Similar to pulse-chase data, AID localized in the nu-
cleus displayed the fastest decay after cycloheximide treatment, 
with similar values of 2.5 and 8 h estimated for the half-lives 
of the MutNES and WT constructs, respectively (unpub-
lished data). 
 AID is polyubiquitinated in the nucleus 
 To determine whether proteasomal activity was involved in 
the nuclear AID degradation pathway in the BL2 cell line, we 
examined the eff ect of the 26S proteasome inhibitor MG132 
on the turnover of AID. BL2 KI cells were incubated with 
the collection of cell fractions according to their position in 
the cell cycle. Each collected fraction was analyzed for both 
AID-EGFP fl uorescence and DNA content by fl ow cytometry, 
thus allowing the correlation of the relative abundance of the 
protein to the various phases of the cell cycle.  Fig. 1 (B and C) 
shows that AID-EGFP increases steadily as the cell gains in 
size and progresses from G1 to G2/M, thus indicating that AID 
is continually expressed throughout the cell cycle. As EGFP-
fl uorescence varied within a factor of two, the expression 
level of AID appears roughly correlated with its gene copy 
number within the cell. 
 Differential accumulation of AID mutant proteins according 
to their subcellular localization 
 To obtain BL2 subclones expressing AID-EGFP with various 
subcellular localizations, we generated tetracycline-inducible 
expression vectors containing WT human AID tagged with 
EGFP (WT-AID-EGFP), or AID-EGFP containing muta-
tions in either the NLS (MutNLS-AID-EGFP) or in the NES 
(MutNES-AID-EGFP), as indicated in  Fig. 2 A . The diff er-
ent constructs were transfected in the BL2 cell line and the 
 Figure 2.  Expression level of EGFP-tagged AID mutant proteins 
correlates with the specifi c cell compartment in which they reside. 
(A) Schematic representation of mutations affecting either the NLS 
(mutNLS, V18S, R19V, according to Shinkura et al. [ 13 ], with numbers 
indicating amino acid positions within the AID protein) or the NES 
(mutNES, L189A, F193A, and L196A), with both domains being repre-
sented as black boxes. (B) FACS analysis of the tetracycline-inducible 
clones, with values of the MFI of the EGFP-positive population. By com-
parison with endogenous AID expression levels in BL2 (corresponding to a 
MFI value of 15 in the KI clone [ Fig. 1 C ]), AID overexpression in EGFP-
positive cells can be estimated at   4 for mutNES-AID, 24 for WT-AID, and 
90 for mutNLS-AID constructs. (C) Confocal images of EGFP signals from 
inducible clones, with or without 2-h LMB treatment, are shown together 
with nuclear staining with propidium iodide (PI) of the same fi eld. Clones 
with a lower percentage of inducible expression are shown, as indicated 
by the presence of EGFP-negative cells in the fi eld, a shut-off of expres-
sion regularly observed in clones kept in culture in induced conditions. 
Bars, 20  μ m. 
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LMB alone did not lead to the appearance of such modifi ed 
forms of AID, but their detection was markedly increased 
when LMB and MG132 were combined. 
 To demonstrate that these high MW species correspond to 
polyubiquitinylated forms of AID, BL2 cells stably transfected 
with an HA-tagged AID – expressing vector were treated with 
LMB or MG132, or with both inhibitors, and proteins were 
extracted after 5 h of incubation and denatured before immuno-
precipitation with agarose-conjugated anti-HA antibodies. 
MG132, total protein extracts were prepared at diff erent time 
points, and the amount of AID and AID-EGFP proteins was 
assessed by Western blot using anti-AID antibodies.  Fig. 4 A 
shows that incubation with MG132 has no obvious eff ect on 
either form of AID. However, when the cells containing 
MutNES-AID-EGFP were incubated with MG132, slower 
migrating protein species were detected ( Fig. 4 B , third lane; 
see also  Fig. 5 C ), suggesting that the nuclear fraction of AID 
is sensitive to inhibition of the proteasome. When the modi-
fi cations of the endogenous protein were studied in the same 
conditions, i.e., by fi rst incubating BL2 cells with LMB for 
1 h to block AID in the nucleus before MG132 addition, mod-
ifi cations were observed for the endogenous AID protein as 
well ( Fig. 4 B , last lane). As incubation with proteasome in-
hibitors results in a stabilization that is not easily quantifi -
able by Western blot, the combined eff ect of MG132 and 
LMB was monitored for a WT-AID-EGFP – expressing clone 
through the evolution of its fl uorescence intensity over time; 
the specifi c fl uorescence decay observed upon nuclear se-
questering of AID was prevented by the inhibition of protea-
somal activity, whereas the fl uorescence of a MutNLS-AID-
EGFP clone treated in the same conditions was not aff ected 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20070950/DC1). These results thus suggest that poly-
ubiquitination as a prelude to proteasomal degradation may 
specifi cally take place in the nucleus. 
 To verify this hypothesis, nuclear and cytoplasmic frac-
tions were extracted from normal BL2 cells after incubation 
with either MG132 or LMB, or both. High molecular weight 
(MW) species were already detectable in the presence of 
MG132 in the minor nuclear AID fraction, whereas they were 
absent in the major cytoplasmic fraction ( Fig. 4 C ). Addition of 
 Figure 3.  The half-life of AID differs according to its subcellular 
localization. (A and B) BL2 clones expressing WT-AID-EGFP, MutNES-AID-
EGFP, or MutNLS-AID-EGFP were metabolically labeled for 1 h with [ 35 S]-
labeled cysteine and methionine and chased for the indicated length of 
time. AID-EGFP was immunoprecipitated from cell lysates with anti-EGFP 
antibody (or anti-AID for the endogenous protein) and subjected to SDS-
PAGE and autoradiography. (C) Immunoprecipitated MutNES-AID-EGFP 
was transferred into nitrocellulose and probed with a monoclonal HRP-
conjugated anti-EGFP antibody to control for immunoprecipitation ef-
fi ciency. (D) Densitometry analysis of autoradiographs of pulse-chase 
immunoprecipitated products, expressed as percentage of initial labeling. 
The data shown are the mean of the results from two experiments. 
 Figure 4.  Ubiquitination of AID and AID-EGFP requires both nu-
clear localization and proteasome inhibition. (A) AID-EGFP knocked-in 
BL2 cells, expressing both AID and AID-EGFP under its endogenous pro-
moter, were incubated with MG132 to inhibit proteasome activity. Cell 
lysates from the indicated time points were analyzed by immunoblotting 
using anti-AID monoclonal antibodies. (B) BL2 cells expressing both en-
dogenous AID and MutNES-AID-EGFP were incubated for 5 h with LMB 
and/or MG132, as indicated. AID status was analyzed as described in A. 
Poly(ADP-ribose) polymerase (PARP; 116 kD) was used as loading control. 
(C) BL2 cells were incubated with LMB, MG132, or both, as indicated. For 
each condition, cytoplasmic (C) and nuclear (N) protein extracts were 
prepared as described in Materials and methods and analyzed by immuno-
blotting, with monoclonal anti-AID antibodies. Anti-PARP antibody was 
used as a nuclear protein control. (D) A BL2 cell line expressing WT-AID-
HA was incubated with LMB or MG132, or both, for 5 h. After treatment, 
cell lysates were denatured and immunoprecipitated with agarose-conju-
gated anti-HA antibodies before SDS-PAGE separation and probing with 
anti-AID (top) or antiubiquitin antibodies (bottom). MW markers and mi-
gration positions of AID-HA are indicated. (E) AID-EGFP knocked-in BL2 
cells were transfected with an HA-tagged ubiquitin-expressing vector and 
either incubated or not with LMB and MG132 for 5 h. Immunoprecipita-
tion was performed 16 h after transfection, as described in D. Western 
blot analysis was performed using anti-AID antibodies. Lanes: C, extract 
before immunoprecipitation (1/10th of total extract); IP, immuno-
precipitated proteins. 
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for both forms of AID expressed from the endogenous loci, 
whether they were EGFP-tagged or not ( Fig. 4 E ). Modifi ed 
forms of AID, although less abundant, were detectable in the 
absence of both inhibitors, a recurrent fi nding when ubiqui-
tin-expressing vectors are transfected, suggesting that such 
massive expression of ubiquitin substrates alone compromises 
the proteasome machinery ( Fig. 5 C and Fig. 6 C ). 
 Although the formation of nonspecifi c aggregates cannot 
be ruled out even in the denaturing conditions used, the con-
vergent results obtained using either Ub-HA – or AID-HA –
 tagged proteins and either antiubiquitin or anti-AID antibodies 
strongly argues against the fact that the detection of high MW 
species of AID could be an artifact. Collectively, these obser-
vations are thus consistent with an essential role of the ubiqui-
tin – proteasomal pathway in the nuclear degradation of AID. 
 No specifi c lysine residue is involved in AID ubiquitination 
 Polyubiquitination proceeds most frequently through the con-
jugation of the fi rst ubiquitin molecule to the   -NH2 moiety 
of a lysine residue within the substrate protein. Five AID mu-
tants, in which one or several lysines were mutated to arginine, 
including a lysineless mutant of AID ( “ Kzero-AID-EGFP ” ; 
The immunoprecipitates were analyzed by Western blotting 
using either anti-AID or -ubiquitin antibodies ( Fig. 4 D ). 
The results showed that treatment with both LMB and MG132 
led to the accumulation of multiple, higher MW species that 
are specifi cally recognized with an antiubiquitin antibody 
( Fig. 4 D , bottom). As an additional control for ubiquitin 
modifi cation of AID, transfection of the BL2 KI cell line was 
performed with Ub-HA – expressing vectors, cells incubated 
with both MG132 and LMB, and denatured extracts immuno-
precipitated with anti-HA antibodies. Western blot analysis 
using anti-AID antibodies revealed slower migrating bands 
 Figure 5.  Lysine mutants of AID are polyubiquitinated in BL2. 
(A) Schematic presentation of the human AID protein sequence along with 
the positions of the lysine residues mutated in the various constructs. 
(B) BL2 clones expressing either WT-AID-EGFP (sample 1, WT), or a lysine-
less mutant of AID (Kzero-AID-EGFP; sample 2, Kzero) were incubated 
with the indicated inhibitors for 5 h. Protein extracts were analyzed by 
immunoblotting with anti-AID. PARP (116 kD) was used as loading control. 
(C) BL2 cell clones stably expressing either WT-AID-EGFP (WT), mutNES-AID-
EGFP (mutNES), a lysineless mutant of AID (Kzero), or the four other AID-
EGFP lysine mutants depicted in A were transiently transfected with an 
HA-tagged ubiquitin-expressing vector and either left untreated (top) or 
incubated with both LMB and MG132 for 5 h (bottom). Denatured lysates 
were immunoprecipitated with agarose-conjugated anti-HA antibodies 
and analyzed by Western blotting using anti-EGFP antibody. Migration 
position of AID-EGFP is indicated. (D) Stable BL2 clones expressing the 
indicated AID-EGFP lysine mutants, WT-AID-EGFP, or mutNLS-AID-EGFP 
were incubated with cycloheximide (CHX, 50  μ g/ml) and LMB (10 ng/ml). 
The decay of the protein was followed by the decrease in fl uorescence 
intensity. The percentage of initial fl uorescence is plotted at various time 
points after addition of the drugs. Kzero1 and 2 represent two indepen-
dent clones. (top) Clones transfected with AID constructs cloned in the 
pIRES puro expression vector; (bottom) clones transfected with tetracy-
cline-inducible pBI expression vectors. 
 Figure 6.  AID is ubiquitinated in the nucleus of activated mouse B 
splenocytes. (A) Purifi ed B cells from mouse spleen were activated by 
incubation with LPS and IL-4. At the indicated days after activation, cells 
were collected and total (T), cytoplasmic (C), or nuclear (N) protein ex-
tracts were prepared as described in Materials and methods and analyzed 
by immunoblotting, with a monoclonal anti – mouse AID antibody. Anti-
nucleolin antibody was used as a nuclear protein control. (B) At day 4, 
activated B cells were treated with LMB and/or MG132, as indicated. SDS-
PAGE – fractionated extracts were probed with anti – mouse AID antibody. 
Actin was used as loading control. (C) At day 2 of IL-4/LPS activation, 2  × 
10 7 cells were transfected with Ub-HA – expressing vector using Amaxa 
nucleofection, as indicated in Materials and methods, and either left un-
treated or incubated for 4 h with both MG132 and LMB, 16 h after trans-
fection. After treatment, cell lysates were denatured and 
immunoprecipitated with agarose-conjugated anti-HA antibodies before 
Western blot analysis with anti-AID monoclonal antibodies. MW markers 
and migration positions of endogenous AID are indicated. 
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and triggers the induction of AID gene expression, to-
gether with an increased accessibility and targeting to the 
S  1 switch region, allowing the cell to undergo CSR in 
culture from IgM to IgG1 ( 18 ). Cells were collected at 
diff erent time points after LPS/IL-4 addition, and total or 
nuclear extracts were prepared as described in Materials 
and methods. As previously reported, AID expression was 
induced 48 h after LPS/IL-4 addition, with a small frac-
tion of the protein being detectable in the nucleus ( Fig. 6 
A )( 19, 20 ). 4 d after stimulation, cells were treated with 
LMB, MG132, or both, followed by total protein extrac-
tion. The direct Western blot analysis using anti – mouse 
AID antibody showed that addition of LMB, together 
with MG132, resulted in the accumulation of AID with the 
appearance of slow migrating forms of the protein ( Fig. 6 B ). 
Transient transfection of a Ub-HA – expressing vector was 
performed in LPS + IL-4 – activated spleen cells 2 d after 
stimulation, and MG132 and LMB were added for 5 h, 16 h 
after transfection. Western blot analysis with an anti-AID 
antibody, after anti-HA immunoprecipitation performed 
as described in the previous section, revealed similarly 
high MW species, thus confi rming that polyubiquitination 
of AID takes place in the nuclei of activated B cells ( Fig. 6 C ). 
As observed for the BL2 cell line, modifi cations were al-
ready observed in the control sample, but were quantita-
tively less important. 
 We next studied whether nuclear destabilization was re-
stricted to the cells naturally expressing AID, i.e., to activated 
B lymphocytes, or whether it constitutes a general regulation 
of AID turnover. To this end, we transiently transfected the hu-
man embryonic kidney 293T cell line with the WT-AID-HA 
depicted in  Fig. 5 A ), were transfected in the BL2 cell line, 
and stable clones were isolated. EGFP fl uorescence decay in 
presence of both LMB and cycloheximide was followed for 
all these mutants, in parallel with WT-AID and mutNLS-
AID – expressing clones. In the four clones with one to four 
lysines mutated, no alteration in the protein decay was ob-
served ( Fig. 5 D , top). The lysineless mutant behaved diff erently, 
being less destabilized by this treatment ( Fig. 5 D , bottom). 
Moreover, incubation with either inhibitor indicated that 
the Kzero-AID-EGFP mutant is not effi  ciently destabilized 
in the presence of LMB, in spite of its nuclear localization 
(Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20070950/DC1), thus indirectly showing that nuclear de-
stabilization is not an artifactual consequence of LMB addi-
tion. Western blot analysis after incubation with LMB, MG132, 
or both revealed that although higher MW species were ob-
served for the lysineless mutant of AID after inhibition of 
both nuclear export and proteasome degradation, this occurred 
at a much lower level than for the WT-AID, thus correlating 
with the very diff erent impact of LMB addition on the stabil-
ity of this protein ( Fig. 5 B ). Accordingly, transfection of 
Ub-HA, followed by anti-HA immunoprecipitation of the 
diff erent lysine mutants, confi rmed a much lower level of 
modifi cation of the Kzero-AID-EGFP protein compared with 
WT-AID, whereas all partial lysine modifi cations had no quan-
titative impact ( Fig. 5 C ). In the control immunoprecipitation 
performed in the absence of both inhibitors, the much higher 
level of modifi cations of the mutNES-AID-EGFP protein 
should be noted ( Fig. 5 C , lane 2), refl ecting, as discussed in 
the previous section, the proteasome saturation eff ect of mas-
sive ubiquitin expression, and which appears specifi cally pro-
nounced for the sole AID mutant that resides in the nucleus 
without LMB addition. 
 No specifi c lysine was thus shown to be involved in AID 
destabilization, whereas the total absence of lysines had a sta-
bilization eff ect that was intermediate between the WT and the 
cytoplasmic-only AID. The residual ubiquitination observed 
could explain this partial eff ect. Two alternative explanations 
are thus possible: either AID is, indeed, polyubiquitinated at its 
N terminus and not at internal lysines, with the low effi  ciency 
observed resulting from a conformational alteration of the pro-
tein induced by the eight mutations introduced. Alternatively, 
polyubiquitination of AID may proceed through several al-
ternative lysine positions, with artifactual and ineffi  cient con-
jugation taking place at its N terminus in the absence of 
internal acceptor sites. 
 Nuclear degradation of AID occurs in normal mouse B cells 
and in a human nonlymphoid cell line 
 We have shown that, in the BL2 Burkitt ’ s lymphoma cell 
line, AID is polyubiquitinated in the nucleus, which leads 
to its rapid degradation via the 26S proteasome. To vali-
date this observation in vivo, we studied the turnover and 
the ubiquitination of AID in mouse splenic B cells stimu-
lated to undergo CSR. The culture of mouse spleen B cells 
in the presence of LPS and IL-4 drives cell proliferation 
 Figure 7.  Nuclear destabilization of AID is not restricted to B cells. 
(A) Human 293T cells transfected with WT-AID-HA – expressing vector were 
incubated for 6 h with both LMB and MG132, or left untreated, as indi-
cated. Immunoprecipitation was performed using agarose-conjugated 
anti-HA antibodies, and SDS-PAGE – fractionated protein extracts were 
analyzed by Western blot with anti-AID antibodies. Migration position of 
AID-HA is indicated. (B) 293T cells stably transfected with a WT-AID-EGFP –
 expressing vector were incubated with cycloheximide (CHX; 20 or 50  μ g/ml) 
and LMB, either separately or in combination, and the decay of the protein 
was followed by the decrease in fl uorescence intensity. The percentage of 
initial fl uorescence is plotted at various time points after addition of the 
inhibitors of protein synthesis and/or protein nuclear export. 
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at G/C positions. Moreover, G-to-A and C-to-T transitions 
predominate in the mutant clones (81%), consistent with a 
high number of C to U deaminations being carried over to rep-
lication. The proportion of transversions, essentially G-to-C 
or C-to-G, was higher in the WT-AID – expressing cell lines 
(45%; unpublished data), suggesting that saturation (or inhibi-
tion) of repair by uracil glycosylase occurs when AID is retained 
in the nucleus. 
 Mutations induced by AID overexpression were also ana-
lyzed at the C  locus, as well as in several non-Ig genes, in-
cluding the AID cDNA sequence of the expression construct, 
in one WT (WT-24) and one mutant (mutNES-16) clone. 
Among non-Ig genes, we selected  BCL6 which is targeted 
by AID and mutated in normal centroblasts ( 22, 23 ),  PAX5 , 
which is mutated in some B cell lymphomas (particularly dif-
fuse large B cell lymphomas, DLBCL) and has been recently 
shown to be targeted by AID, but subjected to error-free re-
pair in normal B cells ( 24 ), and  TP53 , which has not been 
described as mutable in either DLBCL lymphomas or germi-
nal center B cells ( 24, 25 ). A low mutation frequency was 
observed for C μ ,  BCL6 , and  PAX5 genes in the WT clone, 
while being at background level for  TP53 ( Table I ). Muta-
genesis was increased for the  BCL6 gene in the mutNES-16 
clone, but, more surprisingly, also at the  TP53 locus. The 
highest mutation frequency is observed for the AID trans-
gene, in both WT and mutant clones, indicating that the 
strength of the transcriptional activation mediated by the tet-
racycline-regulated CMV promoter can possibly allow the 
targeting of AID at a level comparable to, if not higher than, 
the one occurring at the endogenous V H sequence. However, 
considerable variations in mutagenesis of the AID trans-
gene were observed when all six clones were analyzed (un-
published data), confi rming, as previously reported, that the 
insertion site can infl uence the accessibility to AID-induced 
mutagenesis of transgenes displaying equivalent transcrip-
tional activity ( 26, 27 ). 
 DISCUSSION 
 In this work, we studied additional modes of regulation of 
AID that can impact on the availability of this protein in 
lymphoid cells, and may thus contribute to restrict access to 
its DNA target. The fi rst question asked was whether expres-
sion and/or accumulation of AID were regulated according 
to the cell cycle. We chose the BL2 Burkitt ’ s lymphoma cell 
line for this study. BL2 expresses AID, but it only undergoes 
minimal hypermutation of its immunoglobulin genes consti-
tutively ( 21 ). It is nevertheless likely that this cell line consti-
tutes a valid model for studying the basal regulation of AID 
because it represents the transformed counterpart of a germi-
nal center B cell. 
 KI of EGFP at the  AICDA locus was therefore performed 
in BL2, by fusing EGFP at the end of the last coding exon, 
and various measures showed that AID expression level and 
protein accumulation from both endogenous and KI alleles 
were similar. Fractionation of BL2 by counterfl ow elutriation 
and monitoring of AID-EGFP fl uorescence in elutriated cells 
construct, and studied its ubiquitination in presence of MG132 
and LMB, as described for the BL2 cell line. After anti-HA 
immunoprecipitation and analysis by Western blot, accumu-
lation of high MW species of AID was clearly detectable in 
293T cells ( Fig. 7 A ). 293T cells stably transfected with WT-
AID-EGFP were treated with cycloheximide, LMB, or both, 
and the decay in fl uorescence intensity was followed by 
FACS analysis as described for AID lysine mutants ( Fig. 7 B ). 
Addition of LMB alone was suffi  cient to induce a marked re-
duction in AID protein content, a degradation that was fur-
ther increased by addition of cycloheximide. Thus, nuclear 
destabilization of the AID protein does not appear to be re-
stricted to lymphoid B cells. However, it should be noted 
that although the relative diff erence in stability between the 
shuttling and the nuclear form of the protein appears similar 
in the 293T and the BL2 cell lines, the overall degradation of 
AID seems to occur faster in BL2 (Fig. S4). 
 The NES-AID-EGFP protein is mutagenic in the BL2 cell line 
 Inducible MutNES-AID-EGFP and WT-AID-EGFP con-
structs were transfected in the previously described AID-
defi cient BL2 cell line ( 21 ). Individual clones were isolated, 
expression of AID was induced by tetracycline removal, and 
EGFP-positive cells were isolated by cell sorting 14 d after 
induction. Mutations in the functional V4-39 gene were ana-
lyzed for three mutNES-AID-EGFP and three WT-AID-
EGFP clones. The average mutation frequency for the three 
clones analyzed was 2.3 times higher for the mutant compared 
with WT ones, with larger individual variations being observed 
between the mutant clones (Table S1, available at http://
www.jem.org/cgi/content/full/jem.20070950/DC1). The 
mutNES-16 clone displayed the highest mutation frequency, 
3.2 – 4.5 times higher than any of the WT-AID – expressing 
clones analyzed. Mutations were almost exclusively targeted 
 Table I.  Mutation frequency at various Ig and non-Ig loci 
in BL2 clones transfected with WT-AID-EGFP or mutNES-AID-
EGFP inducible expression vectors 
WT-24 clone mutNES-16 clone
number of mutations/total number of sequences 
 (mutation frequency)
Gene locus 
 (domain sequenced)
V4-39 (390 bp) 13/65 
 (0.51  × 10 -3 )
69/74 
 (2.39  × 10 -3 )
 Cmu (403 bp) 5/74 
 (0.17  × 10 -3 )
6/73 
 (0.20  × 10 -3 )
 BCL6  (640 bp) 3/47 
 (0.10  × 10 -3 )
12/51 
 (0.37  × 10 -3 )
 TP53 (1,064 bp) 1/39 
 (0.024  × 10 -3 )
14/43 
 (0.31  × 10 -3 )
 PAX5 (885 bp) 6/47 
 (0.14  × 10 -3 )
8/46 
 (0.20  × 10 -3 )
AID cDNA (594 bp) 14/22 
 (1.07  × 10 -3 )
39/22 
 (2.98  × 10 -3 )
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cross-linking and degradation. Specifi c interaction between 
cytoplasmic AID and protein factors has indeed been described 
in the Ramos cell line ( 31 ). 
 Nuclear-specifi c degradation of endogenous mouse AID 
was similarly observed in mouse splenic B cells, after its in-
duction by LPS and IL-4 stimulation, indicating that this reg-
ulation is an intrinsic part of its physiological turnover. This 
process is nevertheless not restricted to B cells, as it is similarly 
observed, albeit with some quantitative diff erences, upon 
transfection of the human embryonic kidney 293T cell line. 
 In proteins destined for degradation by the proteasome, 
polyubiquitin chains are commonly anchored to the   -amine 
group of one or several internal lysine residues. To identify 
the putative lysine target within the eight candidate amino 
acids present in the human AID protein, various mutants were 
generated by replacement of lysines by arginines, including a 
lysineless form of AID. No single lysine residue could be 
identifi ed as the internal site of ubiquitin conjugation, as no 
single or multiple (up to four) mutations were able to stabilize 
the nuclear form of the protein. In contrast, the lysineless AID 
was still polyubiquitinated upon addition of proteasome in-
hibitors and sequestration in the nucleus, but at a much lower 
level, and displayed accordingly a nuclear stability intermedi-
ate between the normal and cytoplasmic-only protein. Thus, 
polyubiquitination of AID may proceed through several alter-
native internal sites, as has been shown for the I  B  protein 
( 32 ), the low level of modifi cation still observed in the lysine-
less mutant representing an N-terminal modifi cation that 
would be artifi cially forced. Or, alternatively, N-terminal 
ubiquitination, observed for a few proteins such as the ARF/
INK4a tumor suppressor protein or the MyoD and Id2 tran-
scriptional regulators ( 33 – 36 ), could be the physiological pro-
cess, its relative ineffi  ciency being indirectly generated by the 
eight mutations that would alter the targeting of the ubiquitin 
ligase involved. Stepwise reversion of mutant lysines may al-
low us to settle this issue. 
 The fraction of ubiquitinated AID observed appears to 
always be low in BL2, which may be linked to the intrinsic 
diffi  culty of observing such modifi cations outside the classical 
readouts that 293T cells or fi broblasts constitute. We cannot 
exclude on the other hand that an ubiquitin-independent 
pathway may contribute to AID turnover, as has been recently 
described for the p21 cell cycle regulator, which is channeled 
for proteasomal degradation by the REG  complex in the ab-
sence of ubiquitin cross-linking ( 37, 38 ). In addition to the 
proteasome-mediated nuclear degradation that we have de-
scribed, we do not exclude either that there may be other 
steps at which AID turnover might be regulated, which would 
impact its interaction with other protein partners or its assem-
bly as a dimeric or multimeric complex, for example. 
 The natural target of AID-induced mutagenesis in normal 
germinal center B cells is the Ig locus, as well as several genes 
like  BCL6 , which nevertheless harbor a much lower muta-
tion frequency ( 22, 23, 39 ). Moreover, numerous genes, in-
cluding oncogenes like  PAX5 ,  PIM1 ,  MYC , and  RhoH/TTF , 
which undergo a low level of mutagenesis in some B cell 
showed that AID expression varied approximately within a 
factor of 2 between the G1 and the G2/M phases, i.e., in 
proportion to its gene copy number. AID expression is thus 
not restricted to a specifi c phase of the cell cycle. Expression 
of AID and cytidine deamination throughout the cell cycle fi t 
with current models of hypermutation, and we have proposed 
that mutations at A/T versus G/C bases might result from a 
diff erential handling of the deaminated base, according to its 
occurrence before or during DNA replication ( 28, 29 ). 
 AID has been shown to undergo constant nucleocyto-
plasmic shuttling, with a net balance toward export, thus re-
sulting in a main cytoplasmic localization ( 8 – 12 ). In eff ect, 
incubation of AID-expressing cells with LMB, a specifi c in-
hibitor of CRM1, which is the protein responsible for this 
nuclear export, results in a rapid sequestering of AID in the 
cell nucleus ( 9 ). Alteration of a nuclear export sequence lo-
cated at the 3  end of the AID molecule, as well as of a puta-
tive NLS, has been shown to result in a protein with exclusive 
nuclear or cytoplasmic localization, respectively, a localiza-
tion that is not further altered by addition of LMB ( 9, 10, 13 ). 
We generated such mutants, fused to the EGFP reporter 
gene, and obtained stable tetracycline inducible clones in 
BL2. We noticed that, although these mutants were all ex-
pressed from the same CMV promoter-driven inducible vec-
tors, they displayed markedly diff erent protein expression 
levels that consistently correlated with their specifi c subcellu-
lar localization, suggesting that such a diff erential accumula-
tion might mirror their stability within the cell. The protein 
half-life was determined by either [ 35 S] pulse-chase protein 
labeling or by incubation with cycloheximide and follow up 
of the radioactivity or fl uorescence decay of the AID protein. 
When compared with the normal shuttling protein (WT-
AID-EGFP), the protein sequestered in the nucleus (mutNES-
AID-EGFP) showed a 3 time shorter half-life ( t 1/2 = 2.5 vs. 
8 h), whereas the protein retained in the cytoplasm (mutNLS-
AID-EGFP) was 3 times more stable ( t 1/2 =   20 h), resulting 
in a 10-fold diff erence in stability between the 2 cell com-
partment – restricted mutants of AID. AID nuclear localiza-
tion thus appears to be linked with increased degradation. 
 Degradation of most cellular proteins requires tagging of 
protein substrates by polyubiquitin chains and proceeds via 
an energy-dependent process involving the 26S proteasome 
that constitutes the major neutral proteolytic activity in both 
the cytosol and the nucleus (for review see [ 30 ]). Incubation 
with proteasome inhibitors was shown to result in the ap-
pearance of high MW species of AID that were shown to be 
polyubiquitinylated. However, such modifi cations were es-
sentially observed when AID was retained in the nucleus, ei-
ther because of the addition of LMB or the mutation in the 
nuclear export sequence. We did not observe any ubiquitina-
tion of the cytoplasmic mutant, which displays the longest 
half-life (unpublished data). This could be caused by a modi-
fi cation rate that would be below the detection level of our 
assay, or possibly to a degradation that could be proteasome 
independent. Alternatively, AID could be complexed in the 
cytoplasm with proteins that would protect it from ubiquitin 
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fraction ( 18, 53 ). Phosphorylation at serine 38 has also been 
shown to impact AID activity in vivo ( 31, 53, 54 ). It is 
therefore likely that specifi c posttranslational modifi cations, 
among them phosphorylation, may contribute to sequester 
AID from the nucleus. Such stabilization in chromatin do-
mains would at the same time prevent AID from being con-
stantly exported from the nucleus, while possibly allowing it 
to escape the nuclear-specifi c degradation described in this 
study. This competition between attachment to DNA, deg-
radation and export could also be central in limiting the 
magnitude of AID activity, which has been proposed to be 
mainly nonprocessive ( 55, 56 ), a mode of action that would, 
after each enzymatic round, render this enzyme accessible to 
destabilization and nuclear exclusion. Whether such a com-
petition between phosphorylation and polyubiquitination, 
be it direct or indirect, occurs, and whether additional post-
translational modifi cations, like for example sumoylation, 
orchestrate the assembly of AID into an active mutasome re-
main to be addressed. 
 MATERIALS AND METHODS 
 Construction and transfection of expression vectors for AID mu-
tants.  Full-length cDNA encoding human AID without stop codon was 
fused in frame with the sequence coding for 3 repeats of YPYDVPDYA, 
corresponding to residues 99 – 107 of the infl uenza virus hemagglutinin (HA), 
cloned into pIRESpuro vector. Stable clones were obtained by electropora-
tion in the Burkitt ’ s lymphoma BL2 cell line. HA-tagged ubiquitin-ex-
pressing vector was a gift from M. Treier (European Molecular Biology 
Laboratory, Heidelberg, Germany). Transient transfection was performed 
using the Amaxa device (program C-009). AID-EGFP fusion sequences 
were cloned in the pIRESpuro vector or in the tetracycline-inducible pBI 
expression vector (Clontech Laboratories), in which a blasticidin resistance 
gene amplifi ed from the pcDNA6/TR plasmid (Invitrogen) was inserted in 
its AatII site to allow for selection of transfected clones. The EGFP coding 
sequence was fused at the 3  end of AID. Mutants were constructed by step-
wise PCR mutagenesis, introducing the following mutations. MutNES: 
L189A, F193A, L196A; MutNLS: V18S, R19V ( 13 ); Kzero: all lysines (K10, 
16, 22, 34, 52, 120, 142, 160) mutated to arginines (AAA/G to AGA/G); 
K1-4: fi rst four lysines to arginines; K6-8: last three lysines to arginines; K4, 
K5: fourth and fi fth lysines (positions 34 and 52), respectively, to arginines. 
Inducible vectors were electroporated in the BTZ cell line (a tetracycline-
inducible subclone of BL2, obtained by transfection of the pTet-tTAK vec-
tor [Invitrogen] in which a zeocin resistance gene was inserted [vector and 
cell line provided by M. Muramatsu and T. Honjo, Kyoto University, 
Kyoto, Japan]). Tetracycline-inducible AID-defi cient BL2 clones were ob-
tained by electroporation of the same pTet-tTAK-zeo vector in the 60 – 129 
AID-defi cient cell line ( 21 ). Selection of transfected clones was performed 
in the following conditions: 350 ng/ml puromycin, 5  μ g/ml blasticidin, 
500  μ g/ml zeocin, and 1  μ g/ml tetracycline. Tetracycline-free serum (Clontech 
Laboratories) was used for the culture of inducible clones. 
 Inducible 293T cells were similarly obtained after transfection of the 
pTet-tTAK vector, and inducible WT-AID-EGFP – expressing cells were 
selected as a pool. Transient transfection in 293T was performed using 
Amaxa conditions (program Q-001). 
 Mouse B cell culture, stimulation, and transfection.  B cells were puri-
fi ed from mouse spleen using the mouse B cell isolation kit (Miltenyi Biotec) 
and cultured in complete RPMI 1640 medium with 20 ng/ml murine IL-4 
(PeproTech) and 25  μ g/ml LPS (Sigma-Aldrich). Cells were collected at 
diff erent days after stimulation. 2 d after stimulation, 4  × 10 7 cells were col-
lected and transfected with Ub-HA – expressing vector using the Test Nu-
cleofector kit 104A1 (Amaxa), by sets of 5  × 10 6 cells and 5  μ g of Ub-HA 
lymphomas constitutively expressing AID ( 25, 40 ), appear to 
be targeted by AID in normal B cells, but are spared from 
mutations caused by error-free repair ( 24 ). Deliberate over-
expression of AID has been shown to increase mutation levels 
of several transcribed genes in both prokaryotic and mamma-
lian cells ( 41 – 45 ). However, although the nuclear-restricted 
AID protein induces enhanced mutagenesis both in  Esche-
richia coli and on a transfected substrate in fi broblasts, its mu-
tagenicity in B lymphocytes is not clearly established ( 9, 10 ). 
We obtained inducible clones overexpressing the WT or 
mutant form of AID in the  AICDA   /   BL2 cell line, and 
confi rmed that, although diff erent clones show variable mu-
tation frequencies of their endogenous rearranged V H gene, 
higher mutagenicity can be achieved by the nuclear restricted 
AID compared with the WT one. As nuclear AID is ex-
pressed at a lower level than the normal, shuttling protein, 
the mutagenicity related to the amount of AID protein pres-
ent in a cell is thus 6 – 10-fold higher for a protein with an ex-
clusive nuclear residence. When several non-Ig loci were 
studied in the mutNES-AID-EGFP clone showing the high-
est mutation frequency, mutagenesis at the  BCL6 locus was 
also found to be increased, as well as, and more surprisingly, 
at  TP53 . However, it should be mentioned that, whereas p53 
expression is repressed by Bcl-6 in Burkitt ’ s lymphoma, as 
well as in germinal center B cells, and is thus logically spared 
from hypermutation ( 24, 46 ), its expression has been shown 
to be inducible in specifi c stress conditions in BL2 ( 47 ). The 
 TP53 gene could thus become an AID target in cells that 
failed to repress its expression. Such an AID-induced muta-
genesis of the p53 coding sequence has been recently de-
scribed in human gastric epithelial cells ( 48 ), even though in 
this case mutations were focused in the core p53 coding re-
gion and not in the region studied here, which is located 
downstream from the promoter. Abnormal AID expression 
in nonlymphoid cells could thus unmask additional AID tar-
gets that would become mutated depending on the specifi c 
gene expression profi le of a given cell type, and would thus 
increase the number of genes recently described as susceptible 
to AID deamination ( 24 ). 
 HIGM2 patients with heterozygous or homozygous muta-
tions in the nuclear export sequence of AID do not show 
markedly diff erent mutation frequencies of their endogenous 
Ig genes, suggesting that transcriptional regulation and nuclear 
destabilization during germinal center B cell diff erentiation are 
suffi  cient to keep AID activity under control ( 49, 50 ). How-
ever, in transformed B cells displaying ongoing AID expression 
( 25, 40, 51 ), or in conditions of chronic infl ammation leading 
to AID activation ( 48, 52 ), factors that would modify the nu-
clear turnover of AID could aggravate its oncogenic potential 
and thus contribute actively to aberrant mutagenesis. 
 In conclusion, our study shows that ubiquitin-mediated 
nuclear degradation of AID is part of a multilayer control 
that contributes to the regulation of AID function during 
hypermutation and CSR. A fraction of AID has been de-
tected in activated B cells as being linked to chromatin, and 
phosphorylated AID is found enriched in such a chromatin 
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mined using the BCA protein assay kit (Thermo Fisher Scientifi c). Protein 
samples were mixed with an equal volume of electrophoresis loading buff er 
containing 2% SDS and heated at 95 ° C for 5 min before SDS-PAGE separa-
tion and transfer to nitrocellulose membranes. The membrane was then 
incubated with antibodies, followed by chemiluminescence detection, as 
previously described ( 21 ). 
 Immunoprecipitation was performed after denaturation in immunopre-
cipitation buff er (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 
and protease inhibitor cocktail) plus 1% SDS, and then heated twice for 
5 min at 95 ° C. Supernatants were diluted 10-fold with immunoprecipitation 
buff er containing 5 mM  N -ethylmaleimide and 0.5% NP-40 before anti-
body addition and immunopurifi cation. 
 In addition to our monoclonal anti – human AID antibodies, the following 
antibodies were used: monoclonal anti – mouse AID (Cell Signaling Tech-
nology), monoclonal anti-nucleolin, agarose-conjugated anti-HA (Santa Cruz 
Biotechnology), rabbit polyclonal anti-actin (Abcam), monoclonal anti-
ubiquitin (clone FK2; BioMol), HRP-conjugated monoclonal anti-EGFP 
(Miltenyi Biotec), HRP-coupled anti – mouse and  – rabbit IgG (Bio-Rad 
Laboratories), monoclonal anti-PARP (Serotec), and 7-amino-actinomycin-D 
(BD Biosciences). MG132 and LMB (both from Calbiochem) were used at 
concentrations of 10  μ M and 10 ng/ml, respectively, and cycloheximide 
(Sigma-Aldrich) was used at either 20 or 50  μ g/ml. 
 Online supplemental material.  Supplemental materials and methods de-
scribe the production of the anti – human AID monoclonal antibodies used in 
this study, the generation of the BL2 cell line with EGFP knocked-in at the 
 AICDA locus, and the conditions for the analysis of AID-induced mutations 
at various loci. Fig. S1 compares the protein turnover of AID and AID-EGFP 
expressed from the endogenous loci. Fig. S2 shows the specifi city of the 
anti – human AID monoclonal antibodies used. Fig. S3 shows the eff ect of 
the MG132 proteasome inhibitor on AID stabilization. Fig. S4 shows the 
lack of nuclear destabilization of the lysineless AID mutant. Table S1 de-
scribes the mutation frequency at the V H locus of various AID-expressing 
BL2 clones. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20070950/DC1. 
 We thank Damiana Lecoeuche for excellent technical assistance, Meriem Garfa 
for assistance with confocal microscopy, and J é r ô me M é gret for performing 
cell sorting. We thank T. Honjo and M. Muramatsu for the gift of the pTet-tTAK-
zeo plasmid and the BTZ cell line, and Novartis Pharma (Basel, Switzerland) for 
graciously providing recombinant human IL-4. 
 This work was supported by the Ligue Nationale contre le Cancer (Equipe 
labellis é e) and the European Commission Sixth Framework Program (HYBLIB project, 
NEST pathfi nder program in Synthetic Biology). 
 The authors declare no competing fi nancial interest. 
Submitted:  11 May 2007 
Accepted:  11 April 2008 
 REFERENCES 
  1 .  Jung ,  D. ,  C.  Giallourakis ,  R.  Mostoslavsky , and  F.W.  Alt .  2006 . 
 Mechanism and control of V(D)J recombination at the immunoglobulin 
heavy chain locus.  Annu. Rev. Immunol.  24 : 541 – 570 .  
  2 .  Li ,  Z. ,  C.J.  Woo ,  M.D.  Iglesias-Ussel ,  D.  Ronai , and  M.D.  Scharff  . 
 2004 .  The generation of antibody diversity through somatic hypermuta-
tion and class switch recombination.  Genes Dev.  18 : 1 – 11 .  
  3 .  Muramatsu ,  M. ,  V.S.  Sankaranand ,  S.  Anant ,  M.  Sugai ,  K.  Kinoshita ,  N.O. 
 Davidson , and  T.  Honjo .  1999 .  Specifi c expression of activation-induced 
cytidine deaminase (AID), a novel member of the RNA-editing deami-
nase family in germinal center B cells.  J. Biol. Chem.  274 : 18470 – 18476 .  
  4 .  Muramatsu ,  M. ,  K.  Kinoshita ,  S.  Fagarasan ,  S.  Yamada ,  Y.  Shinkai , and 
 T.  Honjo .  2000 .  Class switch recombination and hypermutation require 
activation-induced cytidine deaminase (AID), a potential RNA editing 
enzyme.  Cell .  102 : 553 – 563 .  
  5 .  Revy ,  P. ,  T.  Muto ,  Y.  Levy ,  F.  Geissmann ,  A.  Plebani ,  O.  Sanal ,  N. 
 Catalan ,  M.  Forveille ,  R.  Dufourcq-Labelouse ,  A.  Gennery ,  et al .  2000 . 
 Activation-induced cytidine deaminase (AID) defi ciency causes the 
DNA per transfection. Increasing the transfection volume to 200  μ l had a 
major incidence on cell viability. Transfection of 2.5  μ g EGFP-expressing 
vector (pMaxGFP, Amaxa) in parallel resulted in 60 – 70% transfection effi  -
ciency and 50% cell viability estimated by 7-amino-actinomycin-D exclu-
sion. Mouse experiments were performed according to the Institut National 
de la Sant é et de la Recherche M é dicale guidelines for laboratory animals 
and approved by the Scientifi c Committee of the Necker Animal Facility. 
 Immunofl uorescence microscopy.  BL2 cells transfected with AID-
EGFP fusion constructs were spun down on poly-lysine – coated glass cover-
slips for 5 min at 100  g . Cells were fi xed in cold methanol for 20 min at 
  20 ° C. Coverslips were mounted on slide using Vectashield mounting me-
dium containing propidium iodide (Vector Laboratories). EGFP fl uorescence 
was visualized using an LSM 510 confocal microscope (Carl Zeiss, Inc.). 
 Flow cytometry, cell sorting, and elutriation.  Transfected BL2 clones 
were analyzed with Cell Quest software on a FACScan apparatus (BD Bio-
sciences). For AID stability estimates, EGFP fl uorescence was measured at 
various time points after cycloheximide, LMB, or MG132 addition. For the 
determination of mutation frequencies, EGFP-positive cells were sorted on a 
FACS Aria cell sorter (Becton Dickinson). Fractionation of BL2 cells accord-
ing to their cell cycle status was performed by counterfl ow elutriation, and 
collected fractions were stained and analyzed for DNA content, as previously 
described ( 21 ), after determination of their EGFP fl uorescence intensity. 
 Pulse-chase assay.  Exponentially growing BL2 cells were washed twice 
with methionine and cysteine-free DME medium, and then incubated at 10 6 
cell/ml in the same medium containing 5% of dialyzed FCS. After 1 h at 
37 ° C, 100  μ Ci/ml of [ 35 S]-L-methionine/cysteine promix (GE Healthcare) 
was added and incubated for an additional 2 h. The medium was then replaced 
with chase medium (RPMI containing 10% FCS and 10-fold excess of cold 
methionine and cysteine). Protein extracts were prepared at various times after 
the chase in radioimmune precipitation assay (RIPA) buff er and the protein 
concentration of each extract was normalized and precleared with protein 
G – agarose before immunoprecipitation. Immunoprecipitation was performed 
using human monoclonal anti-AID or -GFP antibodies (Invitrogen), and pro-
tein G – agarose beads (Santa Cruz Biotechnology). Immunoprecipitated pro-
teins were resolved by SDS-PAGE. Gels were fi xed in 10% acetic acid/40% 
ethanol before being dried and autoradiographed. The half-life curves were 
calculated from densitometry readings of the autoradiograph. 
 Preparation of cytoplasmic and nuclear extracts.  Nuclear and cytoplas-
mic extracts were prepared either from BL2 or from activated mouse B cells, 
as follows: cells were washed twice with cold PBS and suspended in cold hy-
potonic buff er (HB; 10 mM Hepes, pH 7.9, 10 mM KCl, 0.2 mM EDTA, 
1 mM DTT, 1x protease inhibitor mixture [Roche], and 0.25 mM PMSF). 
After incubation on ice for 15 min, NP-40 was added to a fi nal concentration 
of 0.5%. The mixtures were vortexed at high speed for 10 s. The nuclei were 
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collected as cytoplasmic extracts. The pellet was washed once with buff er 
HB, and proteins were extracted by adding high-salt (HS) buff er (20 mM 
Hepes, pH 7.9, 420 mM NaCl, 2 mM EDTA, 1 mM DTT, 1x protease in-
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30 min under gentle agitation. The mixtures were spun at 13,000 rpm for 
15 min, and the supernatants were collected as nuclear extracts. In ubiquitination 
experiments, 10  μ g/ml of N-ethylmaleimide (Sigma-Aldrich) was added to 
PBS during the cell washes and to both the HB and HS buff ers. 
 Total extract preparation, immunoprecipitation, and immuno-
blotting.  The whole-cell protein lysates were washed twice with cold PBS, 
and incubated under agitation in the cold room for 20 min in RIPA (50 mM 
Hepes, pH 7.9, 150 mM NaCl, 1.25 mM EDTA, 0.1% SDS, 0.5% sodium 
deoxycholate, 1% NP-40, 1 mM dithiothreitol, 1x protease inhibitor mix-
ture, and 0.25 mM PMSF). Insoluble material was removed with 30-min 
centrifugation at 15,000 rpm at 4 ° C. The protein concentration was deter-
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